Michael Rome joined Foresite Capital in 2016 and leads the firm’s therapeutics investing practice, which spans company incubation, syndicated private financings, and public markets. Board roles past and present include: Affinivax (observer), Alumis, Avenzo, Candid, CG Oncology (observer), Khartis, Kinnate, KymaThera, Nurix (observer), Pharvaris, RayThera, Remix, Turning Point Therapeutics (observer), and XinThera. Prior to Foresite Capital, he was an analyst at DAFNA Capital Management. He earned a BS in Molecular, Cell, and Developmental Biology from UCLA and a PhD in Biochemistry from Caltech as an NSF Fellow.
Michael Rome, PhD
Managing Director
Highlights
- Head of the therapeutics investment team at Foresite Capital, a multidisciplinary team comprising individuals with expertise in biopharma, finance, and academic science.
- Experience leading company formation, mergers and acquisitions, and private/public company structured financings.
- Board director and officer at multiple publicly traded biotechnology companies.
